Tg Therapeutics (TGTX) Cash & Current Investments (2011 - 2026)

Tg Therapeutics' Cash & Current Investments history runs 16 years deep, the most recent figure standing at $645.0 million for Q1 2026.

• In Q1 2026, Cash & Current Investments rose 133.5% year-over-year to $645.0 million; the TTM figure through Mar 2026 stood at $645.0 million (up 133.5% YoY), while the FY2025 annual figure was $64.1 million, down 51.21% from the prior year.
• Cash & Current Investments was $645.0 million for Q1 2026 at Tg Therapeutics, up from $64.1 million in the prior quarter.
• In the past five years, Cash & Current Investments ranged from a high of $645.0 million in Q1 2026 to a low of $64.1 million in Q4 2025.
• Historically, Cash & Current Investments has averaged $214.0 million across 5 years, with a median of $195.7 million in 2022.
• The sharpest annual moves came in 2025 and 2026: Cash & Current Investments slumped 61.42% in 2025, then surged 133.5% in 2026.
• A 5-year view of Cash & Current Investments shows it stood at $161.7 million in 2022, then jumped by 34.53% to $217.5 million in 2023, then plunged by 39.55% to $131.5 million in 2024, then tumbled by 51.21% to $64.1 million in 2025, then soared by 905.57% to $645.0 million in 2026.
• The last three Cash & Current Investments figures came in at $645.0 million (Q1 2026), $64.1 million (Q4 2025), and $131.6 million (Q3 2025), per Business Quant data.